Last reviewed · How we verify
ApatinibMesylateTablets
ApatinibMesylateTablets is a Tyrosine kinase inhibitor Small molecule drug developed by Chang-Ming Huang, Prof.. It is currently in Phase 2 development for Gastric cancer. Also known as: Oxaliplatin for Injection, Gimeracil and Oteracil Porassium Capsules.
Tyrosine kinase inhibitor
ApatinibMesylateTablets are used in combination with other treatments for neoadjuvant therapy in locally advanced gastric cancer. The specific combination includes ApatinibMesylateTablets with oxaliplatin and gimeracil and oteracil potassium capsules.
-
Baseline phase 2 → approval rate
+15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas). -
Oncology Phase 2 attrition
-2.0pp
Oncology drugs have higher Phase 2-to-Phase 3 attrition than average — many fail to show OS benefit in larger studies.
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2031–2034 | — |
| EMA | EU | 2032–2035 | +0.7 yr |
| MHRA | GB | 2032–2035 | +0.7 yr |
| Health Canada | CA | 2032–2036 | +0.9 yr |
| TGA | AU | 2032–2036 | +1.2 yr |
| PMDA | JP | 2032–2036 | +1.5 yr |
| NMPA | CN | 2033–2037 | +2.3 yr |
| MFDS | KR | 2032–2036 | +1.4 yr |
| CDSCO | IN | 2032–2037 | +1.8 yr |
| ANVISA | BR | 2033–2037 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | ApatinibMesylateTablets |
|---|---|
| Also known as | Oxaliplatin for Injection, Gimeracil and Oteracil Porassium Capsules |
| Sponsor | Chang-Ming Huang, Prof. |
| Drug class | Tyrosine kinase inhibitor |
| Target | VEGFR2 |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 2 |
Mechanism of action
Apatinib mesylate is a small molecule inhibitor of vascular endothelial growth factor receptor 2 (VEGFR2), which plays a key role in angiogenesis and tumor growth.
Approved indications
- Gastric cancer
Common side effects
- Diarrhea
- Fatigue
- Nausea
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ApatinibMesylateTablets CI brief — competitive landscape report
- ApatinibMesylateTablets updates RSS · CI watch RSS
- Chang-Ming Huang, Prof. portfolio CI
Frequently asked questions about ApatinibMesylateTablets
What is ApatinibMesylateTablets?
How does ApatinibMesylateTablets work?
What is ApatinibMesylateTablets used for?
Who makes ApatinibMesylateTablets?
Is ApatinibMesylateTablets also known as anything else?
What drug class is ApatinibMesylateTablets in?
What development phase is ApatinibMesylateTablets in?
What are the side effects of ApatinibMesylateTablets?
What does ApatinibMesylateTablets target?
Related
- Drug class: All Tyrosine kinase inhibitor drugs
- Target: All drugs targeting VEGFR2
- Manufacturer: Chang-Ming Huang, Prof. — full pipeline
- Therapeutic area: All drugs in Oncology
- Indication: Drugs for Gastric cancer
- Also known as: Oxaliplatin for Injection, Gimeracil and Oteracil Porassium Capsules
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing